Open AccessmiRNAs as radio‐response biomarkers for breast cancer stem cells
Author(s) -
GriñánLisón Carmen,
OlivaresUrbano María Auxiliadora,
Jiménez Gema,
LópezRuiz Elena,
Val Coral,
MorataTarifa Cynthia,
Entrena José Manuel,
GonzálezRamírez Amanda Rocío,
Boulaiz Houria,
Zurita Herrera Mercedes,
Núñez María Isabel,
Marchal Juan Antonio
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12635
Subject(s) - radioresistance , cancer research , cancer stem cell , microrna , cancer , radiation therapy , stem cell , biology , breast cancer , metastasis , phenotype , oncology , medicine , gene , microbiology and biotechnology , genetics
In breast cancer (BC), the presence of cancer stem cells (CSCs) has been related to relapse, metastasis, and radioresistance. Radiotherapy (RT) is an extended BC treatment, but is not always effective. CSCs have several mechanisms of radioresistance in place, and some miRNAs are involved in the cellular response to ionizing radiation (IR). Here, we studied how IR affects the expression of miRNAs related to stemness in different molecular BC subtypes. Exposition of BC cells to radiation doses of 2, 4, or 6 Gy affected their phenotype, functional characteristics, pluripotency gene expression, and in vivo tumorigenic capacity. This held true for various molecular subtypes of BC cells (classified by ER, PR and HER‐2 status), and for BC cells either plated in monolayer, or being in suspension as mammospheres. However, the effect of IR on the expression of eight stemness‐ and radioresistance‐related miRNAs (miR‐210, miR‐10b, miR‐182, miR‐142, miR‐221, miR‐21, miR‐93, miR‐15b) varied, depending on cell line subpopulation and clinicopathological features of BC patients. Therefore, clinicopathological features and, potentially also, chemotherapy regimen should be both taken into consideration, for determining a potential miRNA signature by liquid biopsy in BC patients treated with RT. Personalized and precision RT dosage regimes could improve the prognosis, treatment, and survival of BC patients.